Abstract
An end goal of fecal source tracking (FST) is to provide information on risk of transmission of waterborne illnesses associated with fecal contamination. Ideally, concentrations of FST markers in ambient waters would reflect exposure risk. Human mtDNA is an FST marker that is exclusively human in origin and may be elevated in feces of individuals experiencing gastrointestinal inflammation. In this study, we examined whether human mtDNA is elevated in fecal samples from individuals with symptomatic norovirus infections using samples from the US, Mozambique, and Bangladesh. We quantified hCYTB484 (human mtDNA) and HF183/BacR287 (human-associated Bacteroides) FST markers using droplet digital PCR. We observed the greatest difference in concentrations of hCYTB484 when comparing samples from individuals with symptomatic norovirus infections versus individuals without norovirus infections or diarrhea symptoms: log10 increase of 1.42 in US samples (3,820% increase, p-value = 0.062), 0.49 in Mozambique (308% increase, p-value = 0.061), and 0.86 in Bangladesh (648% increase, p-value = 0.035). We did not observe any trends in concentrations of HF183/BacR287 in the same samples. These results suggest concentrations of fecal mtDNA increase during symptomatic norovirus infection and that mtDNA in environmental samples may represent an unambiguously human source-tracking marker that correlates with enteric pathogen exposure risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This material is based upon work supported by the National Science Foundation under Grant Number 1511825 and the United States Geological Survey under Project ID 2018GA388B. We received further support from the Bill and Melinda Gates Foundation grant OPP1137224 and the World Bank Strategic Impact Evaluation Fund (SIEF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Comite Nacional de Bioetica para a Saude (CNBS), Ministerio da Saude (333/CNBS/14), Research Ethics Committee of the London School of Hygiene & Tropical Medicine (reference number 8345), Institutional Review Board of the Georgia Institute of Technology (protocol number H15160), International Centre for Diarrhoeal Diseases Research, Bangladesh (icddr,b) scientific and ethical review committees (protocol number 14022), human subjects institutional review board at Stanford University (protocol number 30456), and the Institutional Review Board of Emory University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Major revisions include: results and discussion updated to include further comparison between HF183/BacR287 and human mtDNA as well as further discussion on limitations of human mtDNA as an FST marker. Table 2 and main text revised to include log10 increases alongside previously included percent increases. Supporting Info updated to include 95% confidence intervals for human mtDNA concentrations.
Data Availability
All data produced are available in the supplementary information (as an Excel file).
